OncoCyte Corporation (OCX)
NASDAQ: OCX · Real-Time Price · USD
3.390
+0.440 (14.92%)
Apr 24, 2025, 4:00 PM EDT - Market closed
OncoCyte Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 1.88 | 1.5 | 0.96 | 2.2 | 1.22 | Upgrade
|
| Revenue Growth (YoY) | 25.15% | 56.89% | -56.42% | 80.76% | - | Upgrade
|
| Cost of Revenue | 1.05 | 1 | 0.88 | 0.7 | 1.86 | Upgrade
|
| Gross Profit | 0.83 | 0.5 | 0.08 | 1.5 | -0.64 | Upgrade
|
| Selling, General & Admin | 14.15 | 13.54 | 21.53 | 20.39 | 22.45 | Upgrade
|
| Research & Development | 9.84 | 9.15 | 7.28 | 4.8 | 9.43 | Upgrade
|
| Operating Expenses | 24.08 | 22.77 | 28.91 | 25.28 | 31.87 | Upgrade
|
| Operating Income | -23.25 | -22.27 | -28.83 | -23.77 | -32.51 | Upgrade
|
| Interest Expense | -0.08 | -0.05 | -0.08 | -0.21 | -0.25 | Upgrade
|
| Earnings From Equity Investments | - | - | - | -0.27 | -1.55 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.46 | 0.39 | -0.06 | -0.04 | 0.03 | Upgrade
|
| EBT Excluding Unusual Items | -22.87 | -21.93 | -28.98 | -24.29 | -34.29 | Upgrade
|
| Merger & Restructuring Charges | - | -0.59 | -1.5 | -2.69 | -1.21 | Upgrade
|
| Impairment of Goodwill | - | - | -18.68 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -0.06 | -0.47 | 0.23 | 0.3 | Upgrade
|
| Asset Writedown | -42.07 | -8.04 | - | - | - | Upgrade
|
| Other Unusual Items | 4.28 | 5.76 | 31.02 | -26.13 | 4.01 | Upgrade
|
| Pretax Income | -60.66 | -24.86 | -18.61 | -52.87 | -31.19 | Upgrade
|
| Income Tax Expense | - | - | - | -9.26 | -1.25 | Upgrade
|
| Earnings From Continuing Operations | -60.66 | -24.86 | -18.61 | -43.61 | -29.93 | Upgrade
|
| Earnings From Discontinued Operations | - | -2.93 | -54.29 | -20.49 | - | Upgrade
|
| Net Income | -60.66 | -27.78 | -72.9 | -64.1 | -29.93 | Upgrade
|
| Preferred Dividends & Other Adjustments | 0.26 | 0.94 | 0.52 | - | - | Upgrade
|
| Net Income to Common | -60.93 | -28.72 | -73.42 | -64.1 | -29.93 | Upgrade
|
| Shares Outstanding (Basic) | 13 | 8 | 6 | 4 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 13 | 8 | 6 | 4 | 3 | Upgrade
|
| Shares Change (YoY) | 70.84% | 38.10% | 24.61% | 35.80% | 27.65% | Upgrade
|
| EPS (Basic) | -4.66 | -3.75 | -13.25 | -14.42 | -9.14 | Upgrade
|
| EPS (Diluted) | -4.66 | -3.75 | -13.25 | -14.42 | -9.14 | Upgrade
|
| Free Cash Flow | -21.23 | -23.61 | -49.91 | -38.19 | -27.21 | Upgrade
|
| Free Cash Flow Per Share | -1.62 | -3.08 | -9.01 | -8.59 | -8.31 | Upgrade
|
| Gross Margin | 44.02% | 33.33% | 8.14% | 68.29% | -52.55% | Upgrade
|
| Operating Margin | -1235.88% | -1481.57% | -3009.50% | -1081.62% | -2673.77% | Upgrade
|
| Profit Margin | -3239.02% | -1911.05% | -7664.09% | -2916.15% | -2461.51% | Upgrade
|
| Free Cash Flow Margin | -1128.60% | -1570.59% | -5209.60% | -1737.40% | -2237.42% | Upgrade
|
| EBITDA | -21.68 | -20.59 | -23.61 | -19.57 | -32.12 | Upgrade
|
| D&A For EBITDA | 1.56 | 1.68 | 5.22 | 4.21 | 0.39 | Upgrade
|
| EBIT | -23.25 | -22.27 | -28.83 | -23.77 | -32.51 | Upgrade
|
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.